Harbin Gloria Pharmaceuticals Cash Flow Reinvestment Rate
Harbin Gloria Pharmaceuticals cash flow reinvestment rate. Harbin Gloria Pharmaceuticals (002437) has a Cash Flow Reinvestment Rate of 0.02x as of September 2025, reinvesting CN¥4.26 Million (capex CN¥4.26 Million ) from operating cash flow of CN¥182.89 Million. Explore 002437 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Harbin Gloria Pharmaceuticals (2007–2025)
Cash flow reinvestment rate of Harbin Gloria Pharmaceuticals from 2007 to 2025. Historical reinvestment intensity for Harbin Gloria Pharmaceuticals across 19 annual periods. Explore 002437 capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
Harbin Gloria Pharmaceuticals Cash Flow Reinvestment Rate by Year (2007–2025)
Harbin Gloria Pharmaceuticals cash flow reinvestment rate by year from 2007 to 2025. Year-by-year capital reinvestment analysis for Harbin Gloria Pharmaceuticals. For the full cash flow conversion analysis, see 002437 cash flow metrics.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.26x | CN¥343.47 Million | CN¥273.36 Million | CN¥23.81 Million | ▲ +589.1% |
| 2024 | 0.18x | CN¥74.93 Million | CN¥410.94 Million | CN¥62.90 Million | ▼ -59.7% |
| 2023 | 0.45x | CN¥124.00 Million | CN¥274.18 Million | CN¥29.62 Million | ▼ -53.9% |
| 2022 | 0.98x | CN¥256.90 Million | CN¥261.62 Million | CN¥33.01 Million | ▲ +306.9% |
| 2021 | 0.24x | CN¥66.17 Million | CN¥274.18 Million | CN¥34.51 Million | ▼ -94.4% |
| 2020 | 4.29x | CN¥54.70 Million | CN¥12.76 Million | CN¥43.66 Million | ▲ +1995.1% |
| 2019 | 0.20x | CN¥124.85 Million | CN¥610.37 Million | CN¥48.43 Million | ▼ -33.3% |
| 2018 | 0.31x | CN¥356.67 Million | CN¥1.16 Billion | CN¥104.34 Million | ▼ -30.0% |
| 2017 | 0.44x | CN¥285.52 Million | CN¥651.80 Million | CN¥194.63 Million | ▲ +14.4% |
| 2016 | 0.38x | CN¥398.39 Million | CN¥1.04 Billion | CN¥185.34 Million | ▼ -39.2% |
| 2015 | 0.63x | CN¥442.37 Million | CN¥702.05 Million | CN¥283.10 Million | ▲ +237.4% |
| 2014 | 0.19x | CN¥125.89 Million | CN¥674.04 Million | CN¥125.89 Million | ▼ -48.2% |
| 2013 | 0.36x | CN¥163.35 Million | CN¥453.02 Million | CN¥163.35 Million | ▼ -48.6% |
| 2012 | 0.70x | CN¥144.37 Million | CN¥205.89 Million | CN¥144.37 Million | ▼ -46.0% |
| 2011 | 1.30x | CN¥166.90 Million | CN¥128.61 Million | CN¥166.90 Million | ▼ -39.3% |
| 2010 | 2.14x | CN¥240.88 Million | CN¥112.59 Million | CN¥240.88 Million | ▲ +494.5% |
| 2009 | 0.36x | CN¥61.47 Million | CN¥170.82 Million | CN¥61.47 Million | ▼ -45.4% |
| 2008 | 0.66x | CN¥38.08 Million | CN¥57.81 Million | CN¥38.08 Million | ▲ +161.3% |
| 2007 | 0.25x | CN¥13.17 Million | CN¥52.26 Million | CN¥13.17 Million | — |